Vancomycin

Articles · Medicine Compliance Aid Stability · Lactation Safety Information · New Medicines ·

42082003

Articles

Medicine Compliance Aid Stability

Vancocin · Flynn Pharma Ltd

Flynn Pharma Ltd
Vancocin
Capsules 125mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from moisture
Powder is hygroscopic. Protect from light and store in airtight container. Maximum 7 days in MCA.
1st April 2015

Lactation Safety Information

Not absorbed from the infant's GI tract
Small amounts in breast milk

New Medicines

AeroVanc · Cystic fibrosis-associated MSRA lung infections - dry powder form in a capsule-based device

Information

AeroVanc
New formulation
Not Known
Savara

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Dry powder inhalation formulation of vancomycin, a glycopeptide antibiotic.
Prevalence is 1 in 2,500 newborn, with calculated carrier frequency of 1 in 25. Over 9,000 people currently have CF in the UK.
Cystic fibrosis-associated MSRA lung infections - dry powder form in a capsule-based device
Inhalation